Ontorpacept
Based on 1 publication(s) in Google Scholar
Ontorpacept (TTI-621) is a soluble fusion protein that consists of the human SIRPα N-terminal (1-118) linked to the Fc region of human IgG1. The N-terminal (1-118)-fragment of ontorpacept is a binding domain for CD47 which is an inhibitor of phagocytosis by macrophages. Ontorpacept is a CD47-blocking checkpoint inhibitor with antitumor activity.
For research use only. We do not sell to patients.
- Purity : 99.57%
- CAS No.: 2131089-46-6
- Molecular Weight:76.43 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Ontorpacept
More
Biological Activity
Description
In Vitro
Ontorpacept (0.001-1000 nmol/L; 2 h) dose-dependently increases macrophage phagocytosis of tumor cells with an average EC50 of 10 nmol/L in primary samples from patients with AML, MDS, multiple myeloma, B-ALL, and T-ALL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NOD.SCID mice with AML cell transplants[1]
-
Dosage:8 mg/kg
-
Administration:Intraperitoneal injection; 8 mg/kg, 3 times a week for 4 weeks
-
Result:Significantly reduced the tumor growth in bone marrow and spleen.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Homo sapiens SIRPA (signal regulatory protein alpha, SHPS1, SIRP, SIRPalpha)-IGHG1 (Fc (Fragment constant)
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Ontorpacept can bind Human CD47 Protein (ECD, His Tag). The EC50 for this effect is 9.12 ng/mL.
Chemical Information
-
CAS No. 2131089-46-6
-
Appearance Liquid
-
Molecular Weight 76.43 kDa
-
Color Colorless to light yellow
-
SMILES
[Ontorpacept]
-
Synonyms
TTI-621
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Transfusion
Anti-CD47 drug interference in pre-transfusion testing can be overcome by antigen masking. [Abstract]2025 Aug 13. PMID: 40799186
Protocols
-
Phagocytosis Functional Assay
A phagocytosis functional assay measures the ability of phagocytic cells, such as neutrophils, macrophages, monocytes, or microglia/macrophages, to bind and internalize particulate targets including bacteria, yeast particles, beads, or myelin particles. Fluorescent flow-cytometry assays detect target uptake as fluorescence associated with gated phagocytes, while pH-sensitive dyes such as pHrodo increase signal in acidic phagosomal compartments and therefore preferentially report internalized particles rather than particles remaining outside the cell. Microscopy or high-content imaging can be used to confirm intracellular localization and, in some protocols, to follow uptake kinetics.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
Purity & Documentation
-
Data Sheet (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)